HomeCompareEXN vs ABBV

EXN vs ABBV: Dividend Comparison 2026

EXN yields 677.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EXN wins by $698060.85M in total portfolio value
10 years
EXN
EXN
● Live price
677.97%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$698060.95M
Annual income
$541,067,584,452.82
Full EXN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EXN vs ABBV

📍 EXN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEXNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EXN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EXN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EXN
Annual income on $10K today (after 15% tax)
$57,627.12/yr
After 10yr DRIP, annual income (after tax)
$459,907,446,784.90/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EXN beats the other by $459,907,425,728.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EXN + ABBV for your $10,000?

EXN: 50%ABBV: 50%
100% ABBV50/50100% EXN
Portfolio after 10yr
$349030.53M
Annual income
$270,533,804,612.29/yr
Blended yield
77.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EXN
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EXN buys
0
ABBV buys
0
No recent congressional trades found for EXN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEXNABBV
Forward yield677.97%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$698060.95M$102.3K
Annual income after 10y$541,067,584,452.82$24,771.77
Total dividends collected$685272.60M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EXN vs ABBV ($10,000, DRIP)

YearEXN PortfolioEXN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$78,497$67,796.61$11,550$430.00+$66.9KEXN
2$581,356$497,364.87$13,472$627.96+$567.9KEXN
3$4,064,621$3,442,569.86$15,906$926.08+$4.05MEXN
4$26,843,663$22,494,518.82$19,071$1,382.55+$26.82MEXN
5$167,562,735$138,840,015.15$23,302$2,095.81+$167.54MEXN
6$989,257,646$809,965,519.98$29,150$3,237.93+$989.23MEXN
7$5,527,550,699$4,469,045,016.92$37,536$5,121.41+$5527.51MEXN
8$29,251,975,998$23,337,496,750.85$50,079$8,338.38+$29251.93MEXN
9$146,722,776,064$115,423,161,745.79$69,753$14,065.80+$146722.71MEXN
10$698,060,954,841$541,067,584,452.82$102,337$24,771.77+$698060.85MEXN

EXN vs ABBV: Complete Analysis 2026

EXNStock

Excellon Resources Inc., a silver mining and exploration company, acquires, explores, develops, and exploits mineral properties in Mexico and Canada. The company primarily explores for silver, lead, zinc, and gold deposits. It holds 100% interests in the Platosa property covering an area of approximately 11,000 hectares located in Durango State, Mexico; the Evolución property that covers an area of 45,000 hectares situated in the states of Durango and Zacatecas, Mexico; and the Silver City Project totaling an area of 164 square kilometers in Saxony, Germany. It also holds 100% interests in the Kilgore Project that covers an area of 6,788 located in Clark County, Southeastern Idaho; and the Oakley Project covering an area of 2,833 hectares in Oakley, Idaho. The company was incorporated in 1987 and is based in Toronto, Canada.

Full EXN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EXN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EXN vs SCHDEXN vs JEPIEXN vs OEXN vs KOEXN vs MAINEXN vs JNJEXN vs MRKEXN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.